Skip to main content

Targeted Therapies

Collection

Guest-edited by:  Prof. Min Li, University of Oklahoma Health Sciences Center (OUHSC), USA
                             Dr. Yanis Boumber, Robert H Lurie Comprehensive Cancer Center, Feinberg                                     School of Medicine, Northwestern University, Chicago, USA 


New Content Item

BMC Medicine and BMC Cancer jointly present the "Targeted Therapies for Cancer" Collection 

Page 1 of 2

  1. Photodynamic therapy (PDT) has become an ideal and promising therapeutic method for fighting cancer, but its common application in clinical practice is prevented by the limitations of expensive devices in ligh...

    Authors: Xing Li, Lijiang Gu, Yuhang Chen, Xiaobing Wang, Yibo Mei, Jinlai Zhou, Minghai Ma, Jianbin Ma, Yue Chong, Xinyang Wang, Peng Guo, Dalin He and Jin Zeng
    Citation: BMC Medicine 2022 20:475
  2. Sorafenib is a multi-kinase inhibitor that shows antitumor activity in advanced hepatocellular carcinoma. Sorafenib exerts a regulatory effect on immune cells, including T cells, natural killer cells and dendr...

    Authors: Xinning Zhang, Yong Xu, Guodong Zhao, Rong Liu and Haisheng Yu
    Citation: BMC Cancer 2022 22:1239
  3. Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies. This study aimed to assess th...

    Authors: Puyuan Xing, Qian Zhao, Li Zhang, Hanping Wang, Dingzhi Huang, Pei Hu, Yinghui Sun and Yuankai Shi
    Citation: BMC Medicine 2022 20:453
  4. Although immune checkpoint inhibitors (ICIs) have influenced the treatment paradigm for multiple solid tumors, increasing evidence suggests that primary and adaptive resistance may limit the long-term efficacy...

    Authors: Pei Zhang, Yang Du, Hua Bai, Zhijie Wang, Jianchun Duan, Xin Wang, Jia Zhong, Rui Wan, Jiachen Xu, Xiran He, Di Wang, Kailun Fei, Ruofei Yu, Jie Tian and Jie Wang
    Citation: BMC Medicine 2022 20:435
  5. Currently, immunotherapy is widely used in the treatment of various stages of non-small cell lung cancer. According to clinical experience and results of previous studies, immunotherapy as neoadjuvant therapy ...

    Authors: Yimin Wang, Chuling Li, Zimu Wang, Zhaofeng Wang, Ranpu Wu, Ying Wu, Yong Song and Hongbing Liu
    Citation: BMC Medicine 2022 20:426
  6. The combination of oncolytic viruses (OVs) with immune checkpoint blockades is a research hotspot and has shown good efficacy. Here, we present the first attempt to combine oncolytic herpes simplex virus 2 (OH...

    Authors: Defeng Kong, Zhenrong Yang, Guoliang Li, Quanyou Wu, Zhaoru Gu, Duo Wan, Qi Zhang, Xiaoli Zhang, Shujun Cheng, Binlei Liu, Kaitai Zhang and Wen Zhang
    Citation: BMC Medicine 2022 20:376
  7. AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks. Topoisomerase-I inhibitor irinotecan is used clinically t...

    Authors: S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith and Todd M. Pitts
    Citation: BMC Cancer 2022 22:1107
  8. The application of combination therapy for cancer treatment is limited due to poor tumor-specific drug delivery and the abscopal effect.

    Authors: Yibin Cheng, Caixia Wang, Huihui Wang, Zhiwei Zhang, Xiaopeng Yang, Yanming Dong, Lixin Ma and Jingwen Luo
    Citation: BMC Medicine 2022 20:411
  9. Structured and harmonized implementation of molecular tumor boards (MTB) for the clinical interpretation of molecular data presents a current challenge for precision oncology. Heterogeneity in the interpretati...

    Authors: Damian T. Rieke, Till de Bortoli, Peter Horak, Mario Lamping, Manuela Benary, Ivan Jelas, Gina Rüter, Johannes Berger, Marit Zettwitz, Niklas Kagelmann, Andreas Kind, Falk Fabian, Dieter Beule, Hanno Glimm, Benedikt Brors, Albrecht Stenzinger…
    Citation: BMC Medicine 2022 20:367
  10. Radiotherapy (RT) is one of the major therapeutic approaches to hepatocellular carcinoma (HCC). Ionizing radiation (IR) inducing the generation of reactive oxygen species (ROS) leads to a promising antitumor e...

    Authors: Yizhi Zhan, Zhanqiao Zhang, Yuechen Liu, Yuan Fang, Yuwen Xie, Yilin Zheng, Guoxin Li, Li Liang and Yi Ding
    Citation: BMC Medicine 2022 20:365
  11. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and ...

    Authors: Tamara K. Moyo, Jason H. Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C. Seegmiller, Aaron T. Gerds, Gregory D. Ayers, Amy E. Dezern, Aziz Nazha, Peter Valent, Arjan A. van de Loosdrecht, Francesco Onida, Lisa Pleyer, Blanca Xicoy Cirici, Raoul Tibes…
    Citation: BMC Cancer 2022 22:1013
  12. Although targeted agents have been gradually applied in the treatment of HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients’ therapeutic demands are far from being met. PATHER2 was the firs...

    Authors: Guangjian Yang, Haiyan Xu, Yaning Yang, Shuyang Zhang, Fei Xu, Xuezhi Hao, Junling Li, Puyuan Xing, Xingsheng Hu, Yutao Liu, Lin Wang, Lin Lin, Zhijie Wang, Jianchun Duan, Jie Wang and Yan Wang
    Citation: BMC Medicine 2022 20:277
  13. Gastrointestinal stromal tumor (GIST) is a rare type of cancer that occurs in the gastrointestinal tract. The majority of GIST cases carry oncogenic forms of KIT, the receptor for stem cell factor (SCF). Small...

    Authors: Dengyang Zhang, Chunxiao He, Yao Guo, Jianfeng Li, Bo Li, Yuming Zhao, Liuting Yu, Zhiguang Chang, Hanzhong Pei, Ming Yang, Na Li, Qi Zhang, Yulong He, Yihang Pan, Zhizhuang Joe Zhao, Changhua Zhang…
    Citation: BMC Medicine 2022 20:257
  14. Significant intertumoral heterogeneity exists as antitumor treatment is introduced. Heterogeneous therapeutic responses are conventionally evaluated by imaging examinations based on Response Evaluation Criteri...

    Authors: Jiawei Lv, Chenfei Wu, Junyan Li, Foping Chen, Shiwei He, Qingmei He, Guanqun Zhou, Jun Ma, Ying Sun, Denghui Wei and Li Lin
    Citation: BMC Medicine 2022 20:268
  15. Although cholesterol metabolism is a common pathway for the development of antitumor drugs, there are no specific targets and drugs for clinical use. Here, based on our previous study of sterol O-acyltransfera...

    Authors: Zhihua Wang, Miaomiao Wang, Mengxin Zhang, Kaikun Xu, Xinshuai Zhang, Yi Xie, Yiming Zhang, Cheng Chang, Xiaolu Li, Aihua Sun and Fuchu He
    Citation: BMC Medicine 2022 20:292
  16. Intraductal carcinoma of the prostate (IDC-P) is a subtype of prostate cancer featured by poor prognosis. Previous studies suggested IDC-P could have a potentially unstable genome. Homologous recombination def...

    Authors: Sha Zhu, Jinge Zhao, Ling Nie, Wenlian Yin, Yaowen Zhang, Fengnian Zhao, Yuchao Ni, Xingming Zhang, Zhipeng Wang, Jindong Dai, Zhenhua Liu, Junru Chen, Yuhao Zeng, Zilin Wang, Guangxi Sun, Jiayu Liang…
    Citation: BMC Medicine 2022 20:237
  17. At present, the extent and clinical relevance of epigenetic differences between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) remain largely unknown. Here, we conducted ...

    Authors: Juan Li, Yuan Liang, Jian Fan, Chunru Xu, Bao Guan, Jianye Zhang, Bin Guo, Yue Shi, Ping Wang, Yezhen Tan, Qi Zhang, Changwei Yuan, Yucai Wu, Liqun Zhou, Weimin Ci and Xuesong Li
    Citation: BMC Medicine 2022 20:222
  18. To investigate the maximum tolerated dose (MTD) of apatinib delivered during and after intensity-modulated radiotherapy (IMRT) for unresectable hepatocellular carcinoma (HCC).

    Authors: Hongzhi Wang, Xianggao Zhu, Yuting Zhao, Dezuo Dong, Lijuan Li, Yong Cai, Yongheng Li and Weihu Wang
    Citation: BMC Cancer 2022 22:771
  19. The FAST study identified claudin-18 (CLDN18.2) as a promising novel therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment and clinicopathological features of CLDN18.2-positive...

    Authors: Keren Jia, Yang Chen, Yu Sun, Yajie Hu, Lei Jiao, Jie Ma, Jiajia Yuan, Changsong Qi, Yanyan Li, Jifang Gong, Jing Gao, Xiaotian Zhang, Jian Li, Cheng Zhang and Lin Shen
    Citation: BMC Medicine 2022 20:223
  20. Cisplatin resistance is one of the main causes of treatment failure and death in head and neck squamous cell carcinoma (HNSCC). A more comprehensive understanding of the cisplatin resistance mechanism and the ...

    Authors: Tong Tong, Xing Qin, Yingying Jiang, Haiyan Guo, Xiaoning Wang, Yan Li, Fei Xie, Hao Lu, Peisong Zhai, Hailong Ma and Jianjun Zhang
    Citation: BMC Medicine 2022 20:231
  21. Cytokines have been reported to alter the response to immune checkpoint inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations. Here, we aimed to identify the key cytokines...

    Authors: Chengming Liu, Lu Yang, Haiyan Xu, Sufei Zheng, Zhanyu Wang, Sihui Wang, Yaning Yang, Shuyang Zhang, Xiaoli Feng, Nan Sun, Yan Wang and Jie He
    Citation: BMC Medicine 2022 20:187

    The Correction to this article has been published in BMC Medicine 2022 20:265

  22. Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC). Despite being an attractive target, CDK4/6 inhibition using pal...

    Authors: Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang and Rong Zhou
    Citation: BMC Medicine 2022 20:175
  23. Diverse genomic breakpoints of fusions that localize to intronic, exonic, or intergenic regions have been identified by DNA next-generation sequencing (NGS), but the role of exonic breakpoints remains elusive....

    Authors: Weihua Li, Rui Wan, Lei Guo, Geyun Chang, Dong Jiang, Lin Meng and Jianming Ying
    Citation: BMC Medicine 2022 20:160
  24. Thymic epithelial tumors (TETs) are rare malignancies and the treatment options are limited. We aimed to evaluate the efficacy and safety of apatinib, an angiogenesis inhibitor, in advanced TETs.

    Authors: Zhengbo Song, Guangyuan Lou, Yina Wang, Zhiping Yang, Wenxian Wang, Yongling Ji, Shiqing Chen, Chunwei Xu, Xiao Hu and Yiping Zhang
    Citation: BMC Medicine 2022 20:154
  25. Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR a/β, and c-kit, had demonstrated prolonged progression-free survival (PFS) in refractory metastatic colorectal...

    Authors: Yue Liu, Qian Xiao, Jinjie He, Hanguang Hu, Jinlin Du, Yuping Zhu, Jiaqi Chen, Zhuo Liu, Jianping Wang, Lifeng Sun, Dong Xu, Jun Li, Xiujun Liao, Jianwei Wang, Yibo Cai, Cheng Cai…
    Citation: BMC Medicine 2022 20:155
  26. HER2-low breast cancers were reported to have distinct clinicopathological characteristics from HER2-zero; however, the difference in their genetic features remains unclear. This study investigated the clinica...

    Authors: Guochun Zhang, Chongyang Ren, Cheukfai Li, Yulei Wang, Bo Chen, Lingzhu Wen, Minghan Jia, Kai Li, Hsiaopei Mok, Li Cao, Xiaoqing Chen, Jiali Lin, Guangnan Wei, Yingzhi Li, Yuchen Zhang, Charles M. Balch…
    Citation: BMC Medicine 2022 20:142
  27. Triple-negative breast cancer (TNBC) is a biologically diverse disease, with characteristics such as homologous recombination deficiency (HRD), gene mutation, and immune reactions. Japan Breast Cancer Research...

    Authors: Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravi Velaga…
    Citation: BMC Medicine 2022 20:136
  28. A significant subset of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastric adenocarcinomas (GAC) are resistant to immune checkpoint inhibitors (ICIs), yet the underlying mechanism...

    Authors: Zhenghang Wang, Xinyu Wang, Yu Xu, Jian Li, Xiaotian Zhang, Zhi Peng, Yajie Hu, Xinya Zhao, Kun Dong, Bei Zhang, Chan Gao, Xiaochen Zhao, Hui Chen, Jinping Cai, Yuezong Bai, Yu Sun…
    Citation: BMC Medicine 2022 20:133
  29. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Sorafenib is the first-line treatment for advanced HCC, but the anti-cancer effects remain to be improved as indi...

    Authors: Zibo Chen, Tao Yuan, Fangjie Yan, Song Ye, Qin Xie, Bo Zhang, Nengmin Lin, Qiaojun He, Bo Yang and Hong Zhu
    Citation: BMC Cancer 2022 22:425
  30. Adding anti-angiogenics to neoadjuvant chemotherapy for localized gastric cancer is recognized as a promising strategy, but its clinical value remains to be defined.

    Authors: Zhaoqing Tang, Yan Wang, Yiyi Yu, Yuehong Cui, Liang Liang, Chen Xu, Zhenbin Shen, Kuntang Shen, Xuefei Wang, Tianshu Liu and Yihong Sun
    Citation: BMC Medicine 2022 20:107
  31. Selinexor 80 mg combined with low-dose dexamethasone (Sd) demonstrated significant clinical benefit in patients with relapsed/refractory multiple myeloma (RRMM) who had disease refractory to a proteasome inhib...

    Authors: Lugui Qiu, Zhongjun Xia, Chengcheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Fei Li, Zhuogang Liu, Xiequn Chen…
    Citation: BMC Medicine 2022 20:108
  32. Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually associated with worse clinical outcomes in men with...

    Authors: Blossom Mak, Hui-Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate Mahon, Martin R. Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett…
    Citation: BMC Medicine 2022 20:112
  33. HER2-low breast cancer (BC) is currently an area of active interest. This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC).

    Authors: Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, Abner Herbert Lim, Seri Park, Yeon Hee Park, Ching-Hung Lin, Yen-Shen Lu, Makiko Ono, Takayuki Ueno, Yoichi Naito, Tatsuya Onishi, Geok-Hoon Lim, Su-Ming Tan, Han-Byoel Lee, Han Suk Ryu…
    Citation: BMC Medicine 2022 20:105
  34. Antagonizing the androgen-receptor (AR) pathway is an effective treatment strategy for patients with metastatic castration-resistant prostate cancer (CRPC). Here, we report the results of a first-in-human phas...

    Authors: Xiaojian Qin, Dongmei Ji, Weijie Gu, Weiqing Han, Hong Luo, Chuanjun Du, Qing Zou, Zhongquan Sun, Chaohong He, Shaoxing Zhu, Tie Chong, Xin Yao, Ben Wan, Xinfeng Yang, Aobing Bai, Chunlei Jin…
    Citation: BMC Medicine 2022 20:84
  35. Breast cancer is the most commonly diagnosed cancer worldwide and is one of the leading causes of cancer death. The incidence, pathological features, and clinical outcomes in breast cancer differ by geographic...

    Authors: Kelly A. Hirko, Gabrielle Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey I. Cutress, Ellen R. Copson, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im and Yeon Hee Park
    Citation: BMC Medicine 2022 20:72
  36. Bevacizumab improves survival outcomes in women diagnosed with epithelial ovarian cancer (EOC). Pre-clinical data showed that the c-MET/VEGFR-2 heterocomplex negates VEGF inhibition through activation of c-MET...

    Authors: Robert D. Morgan, Cristina Ferreras, Isabel Peset, Egle Avizienyte, Andrew G. Renehan, Richard J. Edmondson, Alexander D. Murphy, Shibani Nicum, Thomas Van Brussel, Andrew R. Clamp, Diether Lambrechts, Cong Zhou and Gordon C. Jayson
    Citation: BMC Medicine 2022 20:59
  37. There is currently a lack of effective treatments for non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and potential resistance mechanism to, pyrotinib...

    Authors: Zhengbo Song, Yuping Li, Shiqing Chen, Shenpeng Ying, Shuguang Xu, Jianjin Huang, Dan Wu, Dongqing Lv, Ting Bei, Shuxun Liu, Xiaoping Huang, Congying Xie, Xiaoyu Wu, Jianfei Fu, Feng Hua, Wenxian Wang…
    Citation: BMC Medicine 2022 20:42
  38. Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we evaluated the prognostic role of CTC ge...

    Authors: Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, Emanuela Scarpi, Umberto Basso, Giuseppe Fornarini, Alessandra Mosca, Maurizio Nicodemo, Giuseppe Luigi Banna, Cristian Lolli, Giuseppe Schepisi, Giorgia Ravaglia, Isabella Bondi, Paola Ulivi and Ugo De Giorgi
    Citation: BMC Medicine 2022 20:48
  39. Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative tec...

    Authors: Justyna Mączyńska, Florian Raes, Chiara Da Pieve, Stephen Turnock, Jessica K. R. Boult, Julia Hoebart, Marcin Niedbala, Simon P. Robinson, Kevin J. Harrington, Wojciech Kaspera and Gabriela Kramer-Marek
    Citation: BMC Medicine 2022 20:16

    The Correction to this article has been published in BMC Medicine 2022 20:179

  40. Central nervous system (CNS) metastases in patients with ALK-positive non-small cell lung cancer (NSCLC) are a cause of substantial morbidity and mortality. Although alectinib had demonstrated promising intrac...

    Authors: Zihua Zou, Puyuan Xing, Xuezhi Hao, Yan Wang, Xia Song, Li Shan, Cuiying Zhang, Ziling Liu, Kewei Ma, Guilan Dong and Junling Li
    Citation: BMC Medicine 2022 20:12
  41. Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effect...

    Authors: Jiao Hu, Belaydi Othmane, Anze Yu, Huihuang Li, Zhiyong Cai, Xu Chen, Wenbiao Ren, Jinbo Chen and Xiongbing Zu
    Citation: BMC Medicine 2021 19:289

    The Commentary to this article has been published in BMC Medicine 2021 19:295

  42. Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy—with or without immune checkpoint inhibitors (anti-PDs)—is the current first-line therapy for SCLC...

    Authors: Zhihui Zhang, Chaoqi Zhang, Yuejun Luo, Peng Wu, Guochao Zhang, Qingpeng Zeng, Lide Wang, Zhaoyang Yang, Liyan Xue, Bo Zheng, Hua Zeng, Fengwei Tan, Qi Xue, Shugeng Gao, Nan Sun and Jie He
    Citation: BMC Medicine 2021 19:284

    The Commentary to this article has been published in BMC Medicine 2021 19:295

  43. Multi-omics studies have shown a high and lack of common driver mutations in most thymomas (TH) and thymic carcinomas (TC) that hamper the development of novel treatment approaches. However, deregulation of ap...

    Authors: Denise Müller, Paolo Mazzeo, Raphael Koch, Mark-Sebastian Bösherz, Stefan Welter, Alexander von Hammerstein-Equord, Marc Hinterthaner, Lucia Cordes, Djeda Belharazem, Alexander Marx, Philipp Ströbel and Stefan Küffer
    Citation: BMC Medicine 2021 19:300
  44. In the existing next generation sequencing (NGS) system, epidermal growth factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the category of EGFR exon 19 deletion (19del). H...

    Authors: Yurong Wang, Ruipan Zheng, Peizhu Hu, Ziheng Zhang, Shujing Shen and Xingya Li
    Citation: BMC Cancer 2021 21:1215
  45. The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung c...

    Authors: Yongchang Zhang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Lingli Liu, Qinqin Xu, Haiyan Yang, Wenjuan Jiang, Analyn Lizaso, Luting Qiu, Ting Hou, Jun Liu, Ling Peng and Nong Yang
    Citation: BMC Medicine 2021 19:245
  46. With the identification of new targetable drivers and the recent emergence of novel targeted drugs, using comprehensive genomic profiling in lieu of the routine testing for classic drivers in the clinical care...

    Authors: Shen Zhao, Zhonghan Zhang, Jianhua Zhan, Xin Zhao, Xinru Chen, Liyun Xiao, Kui Wu, Yuxiang Ma, Mengzhen Li, Yunpeng Yang, Wenfeng Fang, Hongyun Zhao and Li Zhang
    Citation: BMC Medicine 2021 19:223
  47. Significant improvements in mortality among patients with non-small cell lung cancer (NSCLC) in the USA over the past two decades have been reported based on Surveillance, Epidemiology, and End Results (SEER) ...

    Authors: Sreeram Ramagopalan, Thomas P. Leahy, Joshua Ray, Samantha Wilkinson, Cormac Sammon and Vivek Subbiah
    Citation: BMC Medicine 2021 19:209
  48. Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking.

    Authors: Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu, Sara Ingles, Khemaies Slimane and Ravindran Kanesvaran
    Citation: BMC Cancer 2021 21:1021

    The Correction to this article has been published in BMC Cancer 2021 21:1191

  49. ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. ...

    Authors: Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou, Jiexia Zhang, Zhengbo Song and Nong Yang
    Citation: BMC Medicine 2021 19:206


Min Li

New Content ItemDr. Min Li is Professor of Medicine, Surgery, and Cell Biology at The University of Oklahoma Health Sciences Center (OUHSC), and holds the George Lynn Cross Research Professorship and the Virginia Kerley Cade Endowed Chair in Cancer Treatment. He is the Assistant Dean for International Research Collaboration at College of Medicine, and Associate Director for Global Oncology at the NCI designated Stephenson Cancer Center (SCC). He is also Director of GI Cancer Research, and Vice Chair for Research at the Department of Surgery, and Co-Leader of Cancer Biology Program of SCC at OUHSC. He is a leading expert on pancreatic cancer (PC), and his research mainly focus on studying PC and brain tumor pathogenesis and developing new therapies. Dr. Li’s group is the first to identify a key zinc transporter ZIP4, which is aberrantly expressed in PC, and promotes cancer growth, cachexia, and metastasis. He has published more than 180 papers and has 3 active NIH R01 grants, and multiple private foundation grants. 

Dr. Li is the council member of the International Association for Pancreatology (IAP), and councilor of the American Pancreatic Association (APA). He will be the President of APA in 2022. He received many awards such as the Outstanding Achievement Award of IAP, and the Provost Research Award. He is an Editorial Advisor for BMC Medicine


Yanis Boumber

New Content ItemYanis Boumber, MD, PhD, Associate Professor, Division of Hematology/ Oncology, Section of Thoracic Head and Neck Medical Oncology, at Northwestern University Cancer Center in Chicago. Dr. Boumber has previously worked as Assistant Professor in the Thoracic Section of the Department of Hematology/Oncology at the Fox Chase Cancer Center, Philadelphia, USA.

Dr Boumber graduated from the Rostov State Medical University, Russia and qualified as MD in 1999. He received his PhD in cancer biology and molecular biology at the University of Texas MD Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences in Houston in 2005. He completed his medicine residency at Good Samaritan hospital, affiliated with Johns Hopkins University in Baltimore in 2010, and medical oncology and hematology fellowship at the University of Texas MD Anderson Cancer Center in 2013.

His research interests include the investigation of signaling pathways and biological processes controlled by MSI2 and developing novel therapeutic approaches to target MSI2 in lung cancer. He joined the editorial board of BMC Cancer in 2016 as Deputy Section Editor. He serves as Senior Board Member since August 2020.

About the Collection

Over the past two decades, significant progress has been made in understanding the molecular mechanisms of cancer, which has led to the development of molecular targeted agents including tyrosine kinase inhibitors, antiangiogenic agents, cell cycle and signalling targeting compounds, PARP inhibitors, DNA methylation inhibitors and antibody-drug conjugates. For many cancers including leukaemia, melanoma, lung, colorectal and breast cancer, targeted therapies have transformed the repertoire of currently available treatments, such as Vemurafenib for BRAF mutated metastatic melanoma and Herceptin for HER2 overexpressing breast cancer. Yet, the responses to targeted therapies are only marginal and short-lived, since many cancers develop resistance leading to disease progression, in addition to patients experiencing toxic side effects and financial burdens associated with treatment.

To overcome the problems associated with tumour resistance, research is focused on developing combination strategies involving targeted therapies and next-generation inhibitors with enhanced efficacy and selectivity. At the same time, molecular approaches are warranted to identify biomarkers and select the most suitable patients to optimise benefit and minimise toxicity.

In recognition of the growing field of research, BMC Medicine and BMC Cancer come together to invite submissions of original research including but not limited to:

  • Novel molecular targeted therapies, such as small molecules, antibodies and drug-antibody conjugates for new tumour targets
  • Resistance to conventional targeted therapies or the development of novel therapeutic targets that overcome targeted therapy resistance
  • Combination therapies involving targeted therapy
  • Discovery of novel serum/tumor biomarkers relevant to targeted therapies in clinical cohorts (e.g. from clinical trials)
  • Identification of genomic biomarkers relevant to targeted therapies through sequencing or bioinformatics (Please note: any bioinformatics studies must be experimentally validated or accompanied by real-world cohorts)
  • Survivorship and toxicology in patients treated with targeted or combination therapy regimens

For more information about each participating journal, including article-processing charges, click on its title below. After submitting to a participating journal, each article will undergo that journal’s full standard peer review process.

BMC Medicine encourages submissions of front matter articles and original research including randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), clinical “Real World” studies, cost-effectiveness analysis, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. For translational research we only consider studies that include patient cohorts or involves human samples. Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered. BMC Medicine does not consider case reports.

Guest Editors provided guidance on the scope of this collection and advised on commissioned content. However, they are not involved in editorial decision-making on papers submitted to this collection. All final editorial decisions are with the Editor-in-Chief, Dr. Lin Lee.​

BMC Cancer encourages submissions of original research and  study protocols reporting on randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), “Real World” studies, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. BMC Cancer does not consider case reports. For pre-clinical and experimental research, we only consider studies that provide results validated in at least 3 relevant cell lines, preferably validated in at least one animal model.  Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered.